USA Europe Asia
Compass AI Login Medtech Pro Login
  • Events
      Featured
      Our Next Event
      Register for LSI USA ‘26
      500+ Investors & Strategics
      See LSI USA '26 Attendee List
      Events Overview
      • Our Summits
      • Who Attends
      • Why Present
      Upcoming Summits
      • LSI USA ‘26
      • LSI Asia ‘26
      • LSI Europe '26
      Past Summits
      • LSI USA ‘25
      • LSI Asia ‘25
      • LSI Europe ‘25
      • Archives
  • Insights
      Featured
      Just Launched
      Compass AI
      New Report
      Emerging Innovators Report
      Compass Al
      Emerging Innovators Report
      Market Data
      Custom Research
  • Magazine
      Featured
      February Edition
      Explore Latest Editions
      The Lens Magazine
      Start Your Subscription
      Magazine
      • The Lens Magazine
      • Explore the Newest Edition
      • Read Free Articles
  • Resources
      Featured
      Released Weekly
      The LSI Alumni Weekly Recap
      Just Released
      2025 LSI Alumni Funding Report
      Resources
      • Research Desk
      • Testimonials
      • Video Library
      • Photo Gallery
  • Company
      Featured
      Our Next Event
      Register for LSI USA '26
      Just Launched
      Compass AI
      Company
      • About Us
      • Our Team
      • Press
  • Contact Us
Contact Us
USA Europe Asia
Compass AI Login Medtech Pro Login
  • Events
  • Insights
  • Magazine
  • Resources
  • Company
Events Overview
  • Our Summits
  • Who Attends
  • Why Present
Upcoming Summits
  • LSI USA ‘26
  • LSI Asia ‘26
  • LSI Europe ‘26
Past Summits
  • LSI USA ‘25
  • LSI Asia ‘25
  • LSI Europe ‘25
  • Archives
Featured
Our Next Event
Register for LSI USA '26
350+ Investors & Strategics
See LSI USA '26 Attendee List
Compass Al
Emerging Innovators Report
Market Data
Custom Research
Featured
Just Launched
Compass AI
New Report
Emerging Innovators Report
Magazine
The Lens Magazine
Explore the Newest Edition
Read Free Articles
Featured
February Edition
Explore Latest Editions
The Lens Magazine
Start Your Subscription
Resources
Research Desk
Testimonials
Video Library
Photo Gallery
Featured
Released Weekly
The LSI Alumni Weekly Recap
Just Released
2025 LSI Alumni Funding Report
Company
About Us
Our Team
Press
Featured
Our Next Event
Register for LSI USA '26
Just Launched
Compass AI
Join our Next Event
LSI USA ‘26, March 16-20, 2026
Waldorf Astoria, Monarch Beach
Register Today
Compass AI
The medtech-specific AI
research platform by LSI
Demo Compass AI
The Lens Magazine
The Lens Medtech
Magazine is LSI's most
curated industry coverage.
  1. Video Library
  2. Founder ≠ CEO | LSI USA '25

Founder ≠ CEO | LSI USA '25

Industry leaders Paul LaViolette, Kelly Constable, Todd Usen, and Dan Sands discuss why the skillsets and roles of founders and CEOs often differ, moderated by Dan Hawkins.
Share social-facebook social-x social-linkedin
View Video Transcript
lsi logo
Contact Us

Upcoming Events

LSI USA ‘26
LSI USA ‘26
March 16-20, 2026
Dana Point, CA
LSI ASIA ‘26
LSI ASIA ‘26
June 30 - July 2, 2026
Singapore
LSI EUROPE ‘26
LSI EUROPE ‘26
Sept 28 - Oct 1, 2026
Barcelona

More From LSI

  • Attend an Event
  • Sponsor an Event
  • Compass, by LSI
  • The Lens, Magazine by LSI

Resources

  • Research Desk
  • Photo Gallery
  • Video Library
  • Testimonials
  • About Us

17011 Beach Blvd, Suite 500 Huntington Beach, CA 92647

714-847-3540

© 2026 Life Science Intelligence, Inc., All Rights Reserved. | Privacy Policy

Request Info
close
STEP 1
close-icon
The Lens - Complimentary Issue
close
close

Subscription Includes

Request Info

Global Medtech Market Analysis & Projections (MAP), 2021-2031
Published:
2023
Next Update:
Q4 2024
Deliverables:
excel pdf report

The Global Medtech Market Analysis and Projections (MAP) provides global market forecasts (2021 – ’31), share-by-supplier data, and analyst insights on 23 major device markets (e.g., Cardiovascular, Orthopedics, Neurovascular, In-Vitro Diagnostics) and 200+ technology subsegments. Understand major market trends and projections across the medtech industry with what medtech strategics and consulting firms have referred to as their “gold standard” for device market sizing data.

Global Surgical Procedure Volumes Dashboard, 2018-2029
Published:
2022
Next Update:
Q2 2024
Deliverables:
excel report

The Global Surgical Procedure Volumes database is the single source of truth for understanding diagnostic and therapeutic procedure volumes on a global scale. With coverage on 37 countries, including the United States, Europe’s Big Five, China, India, Japan and more for 12 major procedure markets (Cardio, Ortho, General Surgery, Radiosurgery, Neuro, OB/GYN and more), this fully interactive database is designed to facilitate one-to-one analyses of procedures, countries, and regions. Data is updated and expanded annually to maintain a consistent pulse on the procedure utilization to empower strategic decisions on commercialization and new product development.

United States Surgical Procedure Volumes, 2018-2029
Published:
2022
Next Update:
Q2 2024
Deliverables:
excel report

The United States Surgical Procedure Volumes Dashboard provides historical and forecasted volumes from 2018 to 2029 for the United States. Understand trends in procedure volume adoption and growth for over 200 procedures across 12 major procedure markets (Cardio, Ortho, General Surgery, OB/GYN, Urology and more). Data is updated and expanded annually to maintain a consistent pulse on the procedure utilization to empower strategic decisions on commercialization and new product development.

Aesthetics, Global Surgical Procedure Volumes, 2018-2029
Published:
2022
Next Update:
Q2 2024
Deliverables:
excel report

The Aesthetics Surgical Procedure Volumes Dashboard provides global, regional, and country-specific historical and projected procedure volumes forecasts from 2018 to 2029. The Aesthetics Procedures Database covers major aesthetic procedures, including: Biopsies, Punch Biopsies, Shave Biopsies, Incisional Biopsies, Lesion Removal Procedures, Curettage, electrocautery, and electrocoagulation lesion destruction, Photodestruction, Cryotherapy-based lesion destruction, Lesion Removal Procedures: Traditional and Other, Abdominoplasty, Blepharoplasty, Breast Augmentation, Breast Lift, Breast Reduction, Buttock Augmentation, Buttock Lift, Cheek Implants, Chin Augmentation, Facelift, Forehead Lift, Gynecomastia Treatment, Hair Transplantation, Lip Augmentation, Liposuction, Lower Body Lift, Otoplasty, Rhinoplasty, Thigh Lift, Upper Arm Lift, Vaginal Rejuvenation, Surgeries for Cleft Palate and Lip, Surgeries for Burn Injuries.

Cardio, Global Surgical Procedure Volumes, 2018-2029
Published:
2022
Next Update:
Q2 2024
Deliverables:
excel report

The Cardiothoracic and Interventional Cardiology Surgical Procedure Volumes Dashboard provides global, regional, and country-specific historical and projected procedure volumes forecasts from 2018 to 2029. The Cardiothoracic and Interventional Cardiology Procedures Database covers major cardiothoracic and interventional cardiology procedures, including: CABG Surgeries Off-Pump CABG, On-Pump CABG, Valve Procedures Aortic Valve Replacements, Mitral Valve Replacements, MV Repairs, AV Repairs, PV Replacements, PV Repairs, TV Operations, Percutaneous Valvuloplasties, Percutaneous Valve Replacements, CHD Surgeries Ventricular Septal Defect Closures, Patent Ductus Arteriosus Repairs, Atrial Septal Defect Closures, Repair of Tetralogy of Fallot, Arterial Shunts Surgeries, Atrioventricular Septal Defect Repairs, Transposition of Great Artery Procedures, Anomalous Pulmonary Venous Return Repairs, Other Congenital Heart Disease Surgeries, Other Cardiothoracic Surgeries Aortic Aneurysm Procedures, Other Cardiothoracic Surgeries, Diagnostic and Therapeutic Catheterizations, Stand-Alone Diagnostic Cardiac Catheterizations, Percutaneous Coronary Interventions, Coronary Interventions Radial Approach, Coronary Interventions Femoral Approach, Heart Rhythm Procedures Conventional Pacemaker Procedures, ICD Procedures, Cardiac Resynchronization Device Procedures, Combined Defib/Resynch Device Procedures, Cardiac Ablations.

ENT, Global Surgical Procedure Volumes, 2018-2029
Published:
2022
Next Update:
Q2 2024
Deliverables:
excel report

The Ear, Nose, and Throat Surgical Procedure Volumes Dashboard provides global, regional, and country-specific historical and projected procedure volumes forecasts from 2018 to 2029. The Ear, Nose, and Throat Surgical Procedures Database covers major ear, nose, and throat procedures, including: Tonsillectomies, Operations on the Ear, FESS, Tracheostomies, Thyroidectomies & Parathyroidectomies, Stand-Alone Adenoidectomies, Tongue Operations, Laryngeal Operations, Pharyngeal Operations, Radical Neck Dissection.

General, Global Surgical Procedure Volumes, 2018-2029
Published:
2022
Next Update:
Q2 2024
Deliverables:
excel report

The General Surgeries Procedure Volumes Dashboard provides global, regional, and country-specific historical and projected procedure volumes forecasts from 2018 to 2029. The General Surgeries Procedures Database covers major general surgical procedures, including: Cholecystectomies Laparoscopic Cholecystectomies, Open Cholecystectomies, Appendectomies, Laparoscopic Appendectomies, Open Appendectomies, Herniorrhaphies Laparoscopic Herniorrhaphies, Open Herniorrhaphies, Bariatric Surgeries Laparoscopic Bariatric, Open Bariatric, Selected Other Endoscopic General & Colorectal Procedures Esophageal (Other Endoscopic), Stomach & Intestinal (Other Endoscopic), Colorectal (Other Endoscopic), Liver (Other Endoscopic), Gallbladder & Biliary (Other Endoscopic), Pancreatic (Other Endoscopic), Other (Other Endoscopic), Other Surgeries Esophageal (Other General, non-Endoscopic), Stomach & Intestinal (Other General, non-Endoscopic), Colorectal (Other General, non-Endoscopic), Liver (Other General, non-Endoscopic), Gallbladder & Biliary (Other General, non-Endoscopic), Pancreatic (Other General, non-Endoscopic), Other (Other General, non-Endoscopic).

Neuro, Global Surgical Procedure Volumes, 2018-2029
Published:
2022
Next Update:
Q2 2024
Deliverables:
excel report

The Neurosurgery Procedure Volumes Dashboard provides global, regional, and country-specific historical and projected procedure volumes forecasts from 2018 to 2029. The Neurosurgery Procedures Database covers major neurosurgical procedures, including: Surgeries for Traumatic Brain Injuries, Ventricular & Shunt Surgeries, New Shunt Placements, Revision Shunt Surgeries, Endoscopic Third Ventriculostomies, Diagnostic Ventricular Endoscopies, Vascular Lesion Procedures, Vascular Lesion Surgeries, Vascular Lesion Coil Procedures, Pituitary Tumor Surgeries, Open Pituitary Tumor Surgeries, Endoscopic Pituitary Tumor Surgeries, Intracranial Tumor Surgeries, Open Intracranial Tumor Surgeries, Endoscopic Intracranial Tumor Surgeries, Cranioplasties, Intracranial Neurostimulation and Peripheral Nerve Procedures, Intracranial Neurostimulator Implant Procedures, Peripheral Nerve Neurostimulation Procedures, Other Peripheral Nerve Procedures.

OB/GYN, Global Surgical Procedure Volumes, 2018-2029
Published:
2022
Next Update:
Q2 2024
Deliverables:
excel report

The Obstetric and Gynecological Surgical Procedure Volumes Dashboard provides global, regional, and country-specific historical and projected procedure volumes forecasts from 2018 to 2029. The Obstetric and Gynecological Surgical Procedures Database covers major obstetric and gynecological procedures, including: Obstetrical Surgeries Cesarean Sections, Destructive Operations, Episiotomies, Other Obstetrical Surgeries, Gynecological Surgeries Colposcopies, Hysterectomies, Salpingo-Oophorectomies & Oophorectomies, Colposcopies, Salpingo-Oophorectomies & Oophorectomies, Hysterectomies, Total Hysterectomies, Subtotal Hysterectomies, Vaginal Hysterectomies, Breast Cancer Surgeries, Breast Reconstruction Surgeries, Breast-Conserving Surgeries, and Mastectomies, among other surgeries.

Ophthalmology, Global Surgical Procedure Volumes, 2018-2029
Published:
2022
Next Update:
Q2 2024
Deliverables:
excel report

The Ophthalmological Surgical Procedure Volumes Dashboard provides global, regional, and country-specific historical and projected procedure volumes forecasts from 2018 to 2029. The Ophthalmological Surgical Procedures Database covers major ophthalmological procedures, including: Cataract Surgeries, Phacoemulsification Surgeries, ICCE Surgeries, ECCE Surgeries, MSICS Surgeries, Refractive Surgeries.

Orthopedic, Global Surgical Procedure Volumes, 2018-2029
Published:
2022
Next Update:
Q2 2024
Deliverables:
excel report

The Orthopedic Surgical Procedure Volumes Dashboard provides global, regional, and country-specific historical and projected procedure volumes forecasts from 2018 to 2029. The Orthopedic Surgical Procedures Database covers major orthopedic procedures, including: Hip Arthroplasties Revision Hip Arthroplasties, Hip Resurfacing Procedures, Primary Hip Arthroplasties - Total Hip, Partial Hip, Knee Arthroplasties Revision Knee Arthroplasties, Primary Knee Arthroplasties - Partial Knee, Primary Knee Arthroplasties - Total Knee, Extremity Fractures Using Hardware Extremity Fractures Using Hardware - Upper Extremities, Extremity Fractures Using Hardware - Fractures of the Femoral Neck & Shaft, Extremity Fractures Using Hardware - Other Lower Extremity, Arthroscopies Knees (Arthroscopies), Shoulders (Arthroscopies), Ankles (Arthroscopies), Feet & Toes (Arthroscopies), Others (Arthroscopies), Other Joint Arthroplasties Finger & Hand, Wrist, Elbow, Shoulder, Ankle & Foot.

Peripheral Vascular, Global Surgical Procedure Volumes, 2018-2029
Published:
2022
Next Update:
Q2 2024
Deliverables:
excel report

The Peripheral Vascular Surgeries Procedure Volumes Dashboard provides global, regional, and country-specific historical and projected procedure volumes forecasts from 2018 to 2029. The Peripheral Vascular Surgeries Procedures Database covers major peripheral vascular procedures, including: Arterial Procedures Thrombectomies & Thromboendarterectomies, Carotid Artery Thrombectomies, Upper Limb Artery Thrombectomies, Iliac Artery Thrombectomies, Renal Artery Thrombectomies, Lower Limb Artery Thrombectomies, Arterial Angioplasties, Carotid Artery Angioplasties, Upper Limb Artery Angioplasties, Iliac Artery Angioplasties, Renal Artery Angioplasties, Lower Limb Artery Angioplasties, Arterial Bypasses, Carotid Artery Bypasses, Upper Limb Artery Bypasses, Iliac Artery Bypasses, Renal Artery Bypasses, Aortofemoral and Aortobifemoral Bypasses, Femoropopliteal Bypasses, Femorotibeal Bypasses, Other Lower Limb Bypasses, Venous Procedures Head, Neck, & Upper Limb Thrombectomies & Thromboendarterectomies of Dialysis Access Venous Segments, Thrombectomies & Thromboendarectomies of Other Upper Limb Veins, Angioplasties of Dialysis Access Venous Segments, Angioplasties of Head, Neck and Other Upper Limb Veins, Lower Limb Venous Procedures Removals of the Saphenous Vein, Removals of Other Veins of the Lower Limbs.

Spine, Global Surgical Procedure Volumes, 2018-2029
Published:
2022
Next Update:
Q2 2024
Deliverables:
excel report

The Spine Surgical Procedure Volumes Dashboard provides global, regional, and country-specific historical and projected procedure volumes forecasts from 2018 to 2029. The Spine Surgical Procedures Database covers major spine procedures, including: Cervical Spine Surgeries Cervical Spine Decompressions, Cervical Spine Discectomies, Cervical Spine Fusions, Cervical Spine Disc Replacements, Thoracic and Deformity Procedures Thoracic Spine Decompressions, Thoracic Spine Discectomies, Thoracic Spine Fusions, Instrumented Procedures for Deformities, Lumbar Procedures Lumbar Spine Decompressions, Lumbar Spine Discectomies, Lumbar Spine Fusions, Insertion of Lumbar Interspinous Process Spacer, Lumbar Spine Disc Replacements, Vertebroplasties & Kyphoplasties Vertebroplasties, Kyphoplasties, Other Spine Surgeries.

SRS, Global Surgical Procedure Volumes, 2018-2029
Published:
2022
Next Update:
Q2 2024
Deliverables:
excel report

The Stereotactic Radiosurgery Procedure Volumes Dashboard provides global, regional, and country-specific historical and projected procedure volumes forecasts from 2018 to 2029. The Stereotactic Radiosurgery Procedures Database covers major stereotactic radiosurgery procedures, including: Intracranial SRS Procedures, Extracranial SRS Procedures, Extracranial Spine Procedures, Extracranial Lung Procedures, Other Extracranial Procedures.

Urological, Global Surgical Procedure Volumes, 2018-2029
Published:
2022
Next Update:
Q2 2024
Deliverables:
excel report

The Urological Surgeries Procedure Volumes Dashboard provides global, regional, and country-specific historical and projected procedure volumes forecasts from 2018 to 2029. The Urological Surgeries Procedures Database covers major urological procedures, including: Kidney Stone Procedures Extra Corporeal Shock Wave Lithotripsy, Percutaneous Nephro Lithotripsy, Ureteroscopies, Open Kidney Stone Procedures, BPH Procedures Transurethral Prostatectomies, Other BPH Surgeries, Prostatectomies, Nephrectomies Partial Nephrectomies, Radical Nephrectomies, Bladder Procedures Therapeutic Endoscopies, Diagnostic Endoscopies, Urethral Catheterizations of Bladder.

Global Markets for Hip Replacement Implants, 2023-2028
Published:
2023
Next Update:
Q2 2024
Deliverables:
excel pdf

This market snapshot from LSI provides an analysis of the global market for hip replacement implants. The market for hip replacement implants includes all prosthetic devices used to replace damaged sections of the hip joint, including those used in total and semi/hemi replacement procedures. This market snapshot is intended to provide a high-level overview of the global market for hip replacement implants, with key insights into: Procedure volumes from 2022 to 2028, Market forecasts from 2022 to 2028, Competitive landscape analysis of major competitors, Insights into key market events for strategics and startups. Companies covered in this report include: B. Braun, DePuy Synthes, DJO Global, Exactech, Johnson & Johnson, Medacta, MicroPort Scientific, Ortho Development, OSSIS, SERF SAS, Smith+Nephew, Symbios Orthopedie, Total Joint Orthopedics, Zimmer Biomet.

Global Markets for Peripheral Vascular Guidewires, 2023-2028
Published:
2023
Next Update:
Q2 2024
Deliverables:
excel pdf

Description coming soon.

Global Markets for Peripheral Atherectomy Catheters, 2023-2028
Published:
2023
Next Update:
Q2 2024
Deliverables:
excel pdf

Description coming soon.

Global Markets for Electrosurgery, 2023-2028
Published:
2023
Next Update:
Q2 2024
Deliverables:
excel pdf

Description coming soon.

Global Markets for Peripheral Vascular Balloons & Vena Cava Filter, 2023-2028
Published:
2023
Next Update:
Q2 2024
Deliverables:
excel pdf

This market snapshot from Life Science Intelligence provides an analysis of the global market for percutaneous transluminal angioplasty (PTA) balloons and inferior vena cava (IVC) filters. A PTA balloon is used in the treatment of peripheral artery disease (PAD) to open a narrowed or blocked artery. IVC filters are permanent or temporary devices to prevent the travel of thrombotic material to the lungs. These devices are frequently used in the management of patients with severe PAD. This market snapshot is intended to provide a high-level overview of the global market for PTA balloons and IVC filters, with key insights into: unit volumes from 2023 to 2028, market forecasts from 2023 to 2028, competitive landscape analysis of major competitors, and insights into key market events for strategics and startups. Companies covered in this report include: Abbott, Acotec Scientific, Adient Medical, B. Braun, BD, Biotronik, Boston Scientific, Brosmed, Cagent Vascular, Cardinal Health, CONMED, Cook Medical, Concept Medical, Cordis, Covellus, Degania Medical, iVascular, Medtronic, Merit Medical, NextStep Medical, Nipro, OrbusNeich, Orchestra BioMed, Philips, Terumo, TriReme Medical.

Global Markets for Mechanical Heart Valves, 2023-2028
Published:
2023
Next Update:
Q2 2024
Deliverables:
excel pdf

Description coming soon.

Global Markets for Tissue Heart Valve Replacement, 2023-2028
Published:
2023
Next Update:
Q2 2030
Deliverables:
excel pdf

Description coming soon.

Global Markets for Transcatheter Mitral Valve Devices, 2023-2028
Published:
2023
Next Update:
Q2 2024
Deliverables:
excel pdf

Description coming soon.

Global Markets for Femoral Closure, 2023-2029
Published:
2023
Next Update:
Q2 2024
Deliverables:
excel pdf

This market snapshot from Life Science Intelligence provides an analysis of the global market for femoral closure devices. Femoral closure devices are used to achieve hemostasis of the hole in the artery that is created to perform catheter-based cardiovascular or endovascular procedures. This market snapshot is intended to provide a high-level overview of the global market for femoral closure devices, with key insights into: unit volumes from 2023 to 2028, market forecasts from 2023 to 2028, competitive landscape analysis of major competitors, insights into key market events for strategics and startups. Companies covered in this report include: Abbott, Cardinal Health, Cardiva, Cordis, CyndRx, Endocor, Haemonetics, Morris Innovative, Rex Medical, Teleflex, Terumo, Transluminal Technologies, Vasorum, Vivasure Medical.

Global Markets for Tricuspid Valve Repair, 2023-2028
Published:
2023
Next Update:
Q2 2024
Deliverables:
excel pdf

This market snapshot from Life Science Intelligence provides an analysis of the global market for tricuspid valve repair devices. Tricuspid valve repair is the preferred surgical approach for the treatment of degenerative tricuspid valve disease. The market is currently experiencing a renaissance with the introduction and development of transcatheter solutions for tricuspid valve repair and replacement. Devices covered within the scope of this analysis include tricuspid valve annuloplasty rings and transcatheter tricuspid valve repair devices. This market snapshot is intended to provide a high-level overview of the global market for tricuspid valve repair devices, with key insights into: unit volumes from 2023 to 2028, market forecasts from 2023 to 2028, competitive landscape analysis of major competitors, and insights into key market events for strategics and startups. Companies covered in this report include: Abbott, CroiValve, Edwards Lifesciences, Innoventric, Medtronic, Mitral Holdco, Mitralix, NaviGate, OrbusNeich, TriCares, Venus Medtech.

Global Markets for Percutaneous Pulmonary Valves, 2023-2028
Published:
2023
Next Update:
Q2 2024
Deliverables:
excel pdf

This market snapshot from Life Science Intelligence provides an analysis of the global market for transcatheter pulmonary valve devices. Pulmonary valve replacement is performed primarily for the treatment of pulmonary valve stenosis, a relatively rare disease associated with congenital heart defects. Devices covered within the scope of this analysis include transcatheter pulmonary valve implants for valve repair and replacement. This market snapshot is intended to provide a high-level overview of the global market for transcatheter pulmonary valve devices, with key insights into: unit volumes from 2023 to 2028, market forecasts from 2023 to 2028, competitive landscape analysis of major competitors, and insights into key market events for strategics and startups. Companies covered in this report include: Edwards Lifesciences, Medtronic, PolyVascular, Venus Medtech.

Global Markets for Coronary Angio Guidewires & Catheters, 2023-2028
Published:
2023
Next Update:
Q2 2024
Deliverables:
excel pdf

This market snapshot from Life Science Intelligence provides an analysis of the global market for coronary angiography catheters and guidewires. These devices are essential to perform coronary angiography, a minimally invasive medical procedure used to visualize blood flow, identify blockages and narrowing of the coronary arteries. Devices covered within the scope of this analysis include coronary angiography catheters and coronary angiography guidewires. This market snapshot is intended to provide a high-level overview of the global market for coronary angiography catheters and guidewires, with key insights into: unit volumes from 2023 to 2028, market forecasts from 2023 to 2028, competitive landscape analysis of major competitors, insights into key market events for strategics and startups. Companies covered in this report include: Abbott, AngioDynamics, B. Braun, Boston Scientific, Cardinal Health, Cook Medical, Cordis, Medtronic, Merit Medical, Philips, Teleflex, Terumo.

Global Markets for Oncology Ablation Devices, 2023-2028
Published:
2023
Next Update:
Q2 2024
Deliverables:
excel pdf

This market snapshot from Life Science Intelligence provides an analysis of the global market for oncology ablation catheters. These devices are used as a therapeutic modality employing energy to selectively destroy cancerous tissue. Devices covered within the scope of this analysis include radiofrequency and microwave ablation electrodes, excluding cryoablation devices, which are covered in a separate report. The snapshot offers a high-level overview of the global market for oncology ablation catheters and guidewires, with key insights into unit volumes and market forecasts from 2023 to 2028, along with a competitive landscape analysis of major competitors and insights into key market events for strategics and startups. Companies covered in this report include: AngioDynamics, Baylis, Boston Scientific, Canyon Medical, CAPS Medical, EDAP, Galvanize Therapeutics, Imagin Medical, Medtronic, Mermaid, Mirai Medical, Monteris, Sonablate, Stryker, TROD Medical, and US Medical Innovations.

Global Markets for ENT Devices, 2023-2028
Published:
2023
Next Update:
Q2 2024
Deliverables:
excel pdf

This market snapshot from Life Science Intelligence provides an analysis of the global market for endoscopic devices for ear, nose, and throat (ENT) surgery. These devices are used to examine and operate on the structures and tissues in the ear, nose, and throat. Devices covered within the scope of this analysis include ENT endoscopic surgical instruments, balloon sinus and dilation catheters, and rigid endoscopes and bronchoscopes. This market snapshot is intended to provide a high-level overview of the global market for ENT endoscopic surgery devices, with key insights into: unit volumes from 2023 to 2028, market forecasts from 2023 to 2028, competitive landscape analysis of major competitors, insights into key market events for strategics and startups. Companies covered in this report include: 3NT Medical, Acclarent, Conmed, Endoluxe, Entellus Medical, Intuitive Surgical, Johnson & Johnson, KARL STORZ, Medtronic, Olympus, Pentax, Pristine Surgical, Richard Wolf, Smith & Nephew, Stryker, Tympany Medical.

Global Markets for Cell Delivery Catheters, 2023-2028
Published:
2023
Next Update:
Q3 2024
Deliverables:
excel pdf

This market snapshot from Life Science Intelligence provides an analysis of the global market for cell delivery catheters. These devices are primarily research-use devices for the delivery of cellular therapies for the treatment of chronic diseases, such as cardiovascular disease and cancer. Devices covered within the scope of this analysis include cell delivery catheters. This market snapshot is intended to provide a high-level overview of the global market for cell delivery catheters, with key insights into: unit volumes from 2023 to 2028, market forecasts from 2023 to 2028, competitive landscape analysis of major competitors, insights into key market events for strategics and startups. Companies covered in this report include: BioCardia, Biosense Webster, Boston Scientific, Cordis, Medtronic, Mercator MedSystems, TriSalus Life Sciences, TRI Medical.

Global Markets for Urology Devices, 2023-2028
Published:
2023
Next Update:
Q3 2024
Deliverables:
excel pdf

This market snapshot from Life Science Intelligence offers an analysis of the global market for urology and renal devices, focusing on treatments for six major conditions: End-stage renal disease (ESRD), Incontinence, Calculi (stones), Benign prostatic hyperplasia (BPH), Prostatitis, and Erectile dysfunction (ED). The devices covered within this analysis encompass a range of tools for diagnosis, treatment, and management, including urinary bags, foley catheters, catheter insertion kits, intermittent catheters, endourology devices, BPH ablation devices, lithotripsy devices, and artificial penis devices. The snapshot provides key insights into unit volumes and market forecasts spanning from 2023 to 2028. Additionally, it includes a competitive landscape analysis of major competitors and insights into key market events for strategics and startups. Companies covered in this report include: 3M, Applied Medical, Astratech, Balton, Baxter Healthcare, B. Braun, BD, Boston Scientific, Calyxo, Corinth Medtech, Coloplast, EndoMed, Flume Catheter Company, Hollister, ICU Medical, Karl Storz, Medline, Medtronic, Merit Medical, Nipro, Olympus, SonoMotion, Teleflex, and Urovision.

Global Markets for External Pain Pumps, 2023-2028
Published:
2023
Next Update:
Q3 2024
Deliverables:
excel pdf

This market snapshot from Life Science Intelligence provides an analysis of the global market for external pain pumps. These devices are used to provide patients with consistent, long-lasting pain relief by delivering pain medication epidurally, intravenously, or subcutaneously. Devices covered within the scope of this analysis include external infusion pumps for pain management. This market snapshot is intended to provide a high-level overview of the global market for external pain pumps, with key insights into: unit volumes from 2023 to 2028, market forecasts from 2023 to 2028, competitive landscape analysis of major competitors, insights into key market events for strategics and startups. Companies covered in this report include: Avanos, B. Braun, BioQ Pharma, Epic Health, ICU Medical, InfuTronix, Medical Flow Systems, Medipacs, MicroPort, Smiths Medical, Teleflex.

Global Markets for Ureteral Access Devices, 2023-2028
Published:
2023
Next Update:
Q3 2024
Deliverables:
excel pdf

This market snapshot from Life Science Intelligence delves into the global market for ureteral access devices, crucial components utilized alongside ureteroscopy or percutaneous nephrolithotomy procedures. These devices facilitate dilation and create a working channel for various urologic interventions. The snapshot aims to offer insights into unit volumes and market forecasts spanning from 2023 to 2028. Additionally, it provides a competitive landscape analysis of major competitors and key market events for strategics and startups. Companies covered in this report include: Amecath, Applied Medical, BD, Boston Scientific, Cook Medical, Envaste, Johnson & Johnson, Mednova, Olympus, Richard Wolf, Rocamed, Teleflex, and Terumo.

Global Markets for Pelvic Floor Repair, 2023-2028
Published:
2023
Next Update:
Q3 2024
Deliverables:
excel pdf

This market snapshot from Life Science Intelligence provides an analysis of the global market for pelvic floor repair mesh. These products are used during surgical procedures to repair prolapse and urinary incontinence. Devices covered within the scope of this analysis include pelvic floor repair/reconstruction mesh. This market snapshot is intended to provide a high-level overview of the global market for pelvic floor repair mesh, with key insights into: unit volumes from 2023 to 2028, market forecasts from 2023 to 2028, competitive landscape analysis of major competitors, and insights into key market events for strategics and startups. Companies covered in this report include: BD, Boston Scientific, Coloplast, Cook Medical, Ethicon, Johnson & Johnson.

Global Markets for Atrial Fibrillation, 2023-2028
Published:
2023
Next Update:
Q3 2024
Deliverables:
excel pdf

Description coming soon.

Global Markets for Neurovascular Devices Ischemic, 2023-2028
Published:
2023
Next Update:
Q3 2024
Deliverables:
excel pdf

This report from Life Science Intelligence analyzes the global market for devices used in the treatment of ischemic stroke, focusing on solutions designed to remove occlusions in blood vessels to prevent and treat this condition. The market snapshot offers insights into unit volumes and market forecasts from 2023 to 2028, along with a competitive landscape analysis of major competitors and key market events for strategics and startups. Companies covered in this report include: Cerenovus, Ceretrieve, Cordis, InNeuroCo, Julier, Medtronic, MicroPort Scientific, Microvention, Penumbra, Phenox, Poseydon Medical, Route 92 Medical, Stryker, and Terumo.

Global Markets for Neuromodulation Devices, 2023-2028
Published:
2023
Next Update:
Q3 2024
Deliverables:
excel pdf

This report from Life Science Intelligence provides an analysis of the global neuromodulation market – a thriving market for managing and treating neurological diseases, chronic pain, and other chronic conditions. Types of neuromodulation, or neurostimulation, devices include implantable and transcutaneous devices, including wearable devices. This market snapshot is intended to provide a high-level overview of the global neuromodulation market, with key insights into: unit volumes from 2023 to 2028, market forecasts from 2023 to 2028, competitive landscape analysis of major competitors, insights into key market events for strategics and startups. Companies covered in this report include: Abbott, Advanced Bionics, Alyve Medical, Axonics, Biotronik, Boston Scientific, EBT Medical, electroCore Medical, Inspire Medical, LivaNova, Medtronic, Neuromod Devices, Nevro.

Global Markets for Vertebroplasty Devices, 2023-2028
Published:
2023
Next Update:
Q3 2024
Deliverables:
excel pdf

This market snapshot from Life Science Intelligence offers an analysis of the global market for vertebral augmentation products, which are crucial in treating vertebral compression fractures, often caused by osteoporosis or spinal tumors. Vertebroplasty and kyphoplasty are the primary surgical interventions, and the market includes products such as vertebroplasty and kyphoplasty cement, as well as delivery devices. The snapshot aims to provide a comprehensive overview of the global vertebral augmentation products market, with key insights into unit volumes and market forecasts from 2023 to 2028. Additionally, it includes a competitive landscape analysis of major competitors and insights into key market events for both established players and startups. Companies covered in this report include: Halma, IZI Medical, Medtronic, Mendec, Merit Medical, RevBio, and Stryker.

Global Markets for TAVI/TAVR, 2023-2028
Published:
2023
Next Update:
Q3 2024
Deliverables:
excel pdf

Global Markets for Drug Delivery, 2023-2028
Published:
2023
Next Update:
Q3 2024
Deliverables:
excel pdf

Global Markets for Benign Prostation Hyperplasia Implants, 2023-2028
Published:
2023
Next Update:
Q3 2024
Deliverables:
excel pdf

This report from Life Science Intelligence provides an analysis of the global market for implants for the treatment of symptomatic benign prostatic hypertrophy/hyperplasia (BPH). These implants are reversible solutions for men suffering from lower urinary tract symptoms (LUTS) caused by prostate enlargement. This market snapshot is intended to provide a high-level overview of the global BPH implants market, with key insights into: unit volumes from 2023 to 2028, market forecasts from 2023 to 2028, competitive landscape analysis of major competitors, and insights into key market events for strategics and startups. Companies covered in this report include: Butterly Medical, Endotherapeutics, Olympus, ProArc, ProVerum, Teleflex, Urotronic, ZenFlow.

Global Markets for Cryoablation, 2023-2028
Published:
2023
Next Update:
Q3 2024
Deliverables:
excel pdf

This report from Life Science Intelligence provides an analysis of the global market for cryoablation devices for non-cardiovascular applications. These devices are used to freeze and induce cellular damage and death for indications including cancer, dermatological conditions, peripheral vascular disease, and urological conditions. This market snapshot is intended to provide a high-level overview of the global cryoablation devices market, with key insights into: unit volumes from 2023 to 2028, market forecasts from 2023 to 2028, competitive landscape analysis of major competitors, insights into key market events for strategics and startups. Companies covered in this report include: Boston Scientific, Brymill Cryogenics, Channel Medsystems, CooperSurgical, CPSI Biotech, CryoConcepts, CryoProbe, CryoSurgery, CSA Medical, Endocare, Endocision, Grand Cryo, Ictero Medical, KryoLife, Mectronic Medical, Sedivention, Siemens Healthineers, Varian Medical Systems, Wallach Surgical.

Global Markets for Diagnostic Electrophysiology Catheters, 2023-2028
Published:
2023
Next Update:
Q3 2024
Deliverables:
excel pdf

This market snapshot from Life Science Intelligence provides an analysis of the global market for diagnostic electrophysiology catheters. These devices are used to measure and map electrical activity within the heart to identify aberrant electrical activity that causes arrhythmias. LSI projects that this market will remain in a high growth phase due to improving technology for the surgical treatment of cardiac arrhythmias and atrial fibrillation (AF). This market snapshot is intended to provide a high-level overview of the global diagnostic electrophysiology catheters market, with key insights into: unit volumes from 2023 to 2028, market forecasts from 2023 to 2028, competitive landscape analysis of major competitors, insights into key market events for strategics and startups. Companies covered in this report include: Abbott, AccuPulse, Acutus Medical, BD, Biosense Webster, Boston Scientific, CardioNXT, CoreMap, Johnson & Johnson, Kardium, Medtronic, MicroPort Scientific, Stereotaxis.

Global Markets for Hernia Repair, 2023-2028
Published:
2023
Next Update:
Q4 2024
Deliverables:
excel pdf

This market snapshot from Life Science Intelligence (LSI) provides an analysis of the global market for hernia mesh products for the surgical repair of hernias. The global market for hernia mesh products is projected to see moderate growth throughout the forecast period covered by the analysis. While the market has been negatively impacted by ongoing lawsuits associated with product complications, the next generation of products has helped the market to recover for one of the most performed abdominal surgeries. This market snapshot is intended to provide a high-level overview of the global market for hernia mesh products, with key insights into: unit volumes from 2023 to 2028, market forecasts from 2023 to 2028, competitive landscape analysis of major competitors, insights into key market events for strategics and startups. Companies covered in this report include: Allergan, Ariste Medical, BD, Cook Medical, Deep Blue Medical Advances, Ethicon, Exogenesis, Integra Lifesciences, Johnson & Johnson, LifeCell, Medtronic, Novus Scientific, Tarian Medical, TELA Bio, TISSIUM, W.L. Gore.

Global Markets for CRM Devices, 2023-2028
Published:
2023
Next Update:
Q4 2024
Deliverables:
excel pdf

This market snapshot from Life Science Intelligence provides an analysis of the global market for cardiac rhythm management (CRM) devices, including pacemakers, implantable cardioverter defibrillators (ICDs), and cardiac resynchronization therapy devices (CRT-Ds). These implantable devices are used to restore the natural rhythm and function of the heart that can be impaired as a result of cardiac rhythm disorders and heart failure. This market snapshot is intended to provide a high-level overview of the global CRM devices market, with key insights into: unit volumes from 2023 to 2028, market forecasts from 2023 to 2028, competitive landscape analysis of major competitors, insights into key market events for strategics and startups. Companies covered in this report include: Abbott, AtaCor Medical, BioTrace Medical, Biotronik, Boston Scientific, Cairdac, Electroducer, FineHeart, Lepu Medical, LivaNova, Medico, Medtronic, Merit Medical, Microport Scientific, Osypka Medical, Pacetronix.

Global Markets for Neurovascular Devices Hemorrhagic, 2023-2028
Published:
2023
Next Update:
Q4 2024
Deliverables:
excel pdf

This report from Life Science Intelligence provides an analysis of the global market for neurovascular devices for the treatment of hemorrhagic stroke. These solutions are used to treat intracerebral bleeds, ruptured aneurysms, and other neurovascular deformities that lead to the pooling of blood vessels that have ruptured inside and outside of the brain. This market snapshot is intended to provide a high-level overview of the global market for neurovascular devices for hemorrhagic stroke, with key insights into: unit volumes from 2023 to 2028, market forecasts from 2023 to 2028, competitive landscape analysis of major competitors, insights into key market events for strategics and startups. Companies covered in this report include: Acandis, Artio Medical, Endostream Medical, Medtronic, MicroPort Scientific, Microvention, Phenox, Penumbra, Rapid Medical, Shape Memory Medical, Stryker, Terumo, Wallaby Medical.

Global Markets for Renal Denervation, 2023-2028
Published:
2023
Next Update:
Q4 2024
Deliverables:
excel pdf

This market snapshot from Life Science Intelligence provides an analysis of the global market for renal denervation devices for the treatment of refractory hypertension (i.e., high blood pressure that does not respond to pharmaceuticals). The market for renal denervation devices includes radiofrequency and ultrasound catheters which are used to ablate the renal nerves. This market snapshot is intended to provide a high-level overview of the global market for renal denervation devices, with key insights into: unit volumes from 2023 to 2028, market forecasts from 2023 to 2028, competitive landscape analysis of major competitors, and insights into key market events for strategics and startups. Companies covered in this report include: Ablative Solutions, Brattea, Medtronic, Metavention, Otsuka Medical, ReCor Medical, SoniVie.

Global Markets for Upper+Lower Suture Anchors, 2023-2028
Published:
2023
Next Update:
Q4 2024
Deliverables:
excel pdf

This market snapshot from Life Science Intelligence analyzes the global market for suture anchors used in upper and lower extremity repair and reconstruction procedures. Suture anchors play a critical role in securing soft tissue to bone, particularly for severe soft tissue tears. The market encompasses bioabsorbable, biocomposite, metallic, and PEEK suture anchors. The snapshot aims to offer insights into unit volumes and market forecasts from 2023 to 2028, along with a competitive landscape analysis of major competitors and key market events for strategics and startups. Companies covered in this report include: Acumed, Acuitive Technologies, aevumed, Anika Therapeutics, Arthrex, ConMed, DePuy Synthes, Johnson & Johnson, Mitek, OSSIO, Paragon 28, Responsive Arthroscopy, Riverpoint Medical, Smith & Nephew, Stryker, and Zimmer Biomet.

Global Markets for Peripheral Stents, 2023-2028
Published:
2023
Next Update:
Q4 2024
Deliverables:
excel pdf

This market snapshot from Life Science Intelligence provides an analysis of the global market for biliary and peripheral vascular stents. These devices are used to maintain and restore patency to anatomical ducts or vessels that have become obstructed due to the formation of plaque, narrowing of the natural lumen, or presence of benign and malignant growths. This market snapshot is intended to provide a high-level overview of the global peripheral vascular and biliary stents market, with key insights into: unit volumes from 2023 to 2028, market forecasts from 2023 to 2028, competitive landscape analysis of major competitors, and insights into key market events for strategics and startups. Companies covered in this report include: Abbott, BD, Biotronik, Boston Scientific, Bryan Medical, Cardinal Health, Cook Medical, Cordis, Endo GI Medical, Hood Labs, Maquet, Medtronic, Merit Medical, MicroPort Scientific, Olympus, Q3 Medical, Zorion Medical.

Global Markets for Electromagnetic Navigation Systems, 2023-2028
Published:
2023
Next Update:
Q4 2024
Deliverables:
excel pdf

This market snapshot from Life Science Intelligence provides an analysis of the global market for electromagnetic navigation systems for tracking, guiding, and positioning instruments during surgery. These systems provide surgeons and the surgical team with real-time information on the position and orientation of instruments used during open and minimally invasive surgeries. This market snapshot is intended to provide a high-level overview of the global electromagnetic navigation systems market, with key insights into: unit volumes from 2023 to 2028, market forecasts from 2023 to 2028, competitive landscape analysis of major competitors, insights into key market events for strategics and startups. Companies covered in this report include: Brainlab, Collin Medical, Elucent Medical, Fiagon, Heal Force, Joimax, Karl Storz, Medtronic, Olympus, Stryker, Veran Medical Technologies.

Global Markets for GI Endoscopy, 2023-2028
Published:
2023
Next Update:
Q4 2024
Deliverables:
excel pdf

This market snapshot report from Life Science Intelligence provides an analysis of the global market for gastrointestinal (GI) endoscopic devices. These devices are used to visualize, diagnose, and surgically treat conditions of the GI tract. The market for GI endoscopic devices includes endoscopes and endoscopic instruments. This market snapshot is intended to provide a high-level overview of the global market for GI endoscopic devices, with key insights into: unit volumes from 2023 to 2028, market forecasts from 2023 to 2028, competitive landscape analysis of major competitors, insights into key market events for strategics and startups. Companies covered in this report include: Ambu, Applied Medical, Aqua Medical, Aspero Medical, B. Braun, Boston Scientific, ConMed, Endoluxe, Ethicon, Integra Lifesciences, Intuitive Surgical, IQ Endoscopes, Johnson & Johnson, Karl Storz, Medtronic, MiWendo Solutions, Olympus, Purple Surgical, Richard Wolf, Stryker, Teleflex.

Global Markets for Hemodialysis, 2023-2028
Published:
2023
Next Update:
Q4 2024
Deliverables:
excel pdf

This market snapshot from Life Science Intelligence provides an analysis of the global market for hemodialysis solutions. Hemodialysis is an essential treatment for patients suffering from end-stage renal disease due to kidney failure. Hemodialysis systems, catheters, and dialyzers are components integral to hemodialysis treatment. This market snapshot is intended to provide a high-level overview of the global hemodialysis solutions market, with key insights into: unit volumes from 2023 to 2028, market forecasts from 2023 to 2028, competitive landscape analysis of major competitors, insights into key market events for strategics and startups. Companies covered in this report include: Asahei Kasei, AngioDynamics, B. Braun, Baxter, Bellco, Byonyks, Diality, Fresenius, Hemoclean, Humacyte, Intermedt, Inspira Health, iRen-MEDICAL, Medivators, Merit Medical, NextKidney, Nikkiso, Nipro, Rockwell Medical, Telelfex, Terumo, Toray Medical, TVA Medical, Vantive.

Globals Markets for Cardiac Ablation, 2023-2028
Published:
Next Update:
Deliverables:

This market snapshot from Life Science Intelligence provides an analysis of the global market for cardiac ablation devices, which are used for the treatment of arrhythmic heart conditions, such as atrial fibrillation. The market for cardiac ablations devices is projected to see strong growth throughout the forecast period covered by this analysis, driven by demographic trends and the adoption of new technologies for the treatment of new ablation technologies, such as Pulsed Field Ablation. Devices covered within the scope of this analysis include cardiac ablation catheters. This market snapshot is intended to provide a high-level overview of the global market for cardiac ablation devices, with key insights into: unit volumes from 2023 to 2028, market forecasts from 2023 to 2028, competitive landscape analysis of major competitors, insights into key market events for strategics and startups. Companies covered in this report include: Abbott, Adagio Medical, AtriAN Medical, AtriCure, Biosense Webster, Boston Scientific, Electrophysiology Frontiers, Field Medical, Galvanize Therapeutics, Healium Medical, Johnson & Johnson, Medtronic, Stereotaxis.

Global Markets for Atrial Septal Occlusion, 2023-2028
Published:
2023
Next Update:
Q4 2024
Deliverables:
excel pdf

This market snapshot from Life Science Intelligence provides an analysis of the global market for atrial septal occlusion devices. These devices are used to close atrial septal defects (ASDs), an abnormal hole in the wall of the upper chambers of the heart that are present at birth. This market snapshot is intended to provide a high-level overview of the global ASD occlusion devices market, with key insights into: unit volumes from 2023 to 2028, market forecasts from 2023 to 2028, competitive landscape analysis of major competitors, insights into key market events for strategics and startups. Companies covered in this report include: Abbott, atHeart Medical, Cardia, Hanyu Medical, Lifetech Scientific, Occlutech, W.L. Gore.

Global Markets for Aortic Grafts, 2023-2028
Published:
2023
Next Update:
Q4 2024
Deliverables:
excel pdf

This market snapshot from LSI provides an analysis of the global market for aortic stent grafts for the treatment of aortic aneurysm. The market for aortic stent grafts includes open (surgical) and endovascular (transcatheter) aortic stent grafts used in the repair of abdominal aortic aneurysm (AAA) and thoracic aortic aneurysm (TAA). This market snapshot is intended to provide a high-level overview of the global market for aortic stent grafts, with key insights into: unit volumes from 2023 to 2028, market forecasts from 2023 to 2028, competitive landscape analysis of major competitors, insights into key market events for strategics and startups. Companies covered in this report include: Cook Medical, Endoron, Endospan, Lombard Medical, Medtronic, MicroPort Scientific, Taurus Vascular, Terumo, TripleMed, W.L. Gore.

Global Markets for Interventional Cardiology Devices, 2023-2028
Published:
2023
Next Update:
Q4 2024
Deliverables:
excel pdf

This market snapshot from LSI provides an analysis of the global market for interventional cardiology devices for the treatment of cardiovascular diseases such as heart failure or severe atherosclerosis. The market for interventional cardiology devices includes devices used to diagnose and treat diseases related to the coronary arteries. Devices included within the scope of this report include coronary stents, catheters, angioplasty balloons, guidewires, and intravascular ultrasound catheters. This market snapshot is intended to provide a high-level overview of the global market for interventional cardiology devices, with key insights into: unit volumes from 2023 to 2028, market forecasts from 2023 to 2028, competitive landscape analysis of major competitors, insights into key market events for strategics and startups. Companies covered in this report include: Abbott, Advanced Bifurcation Systems, B. Braun, BD, Boston Scientific, Cardinal Health, Cook Medical, Corflow Therapeutics, Fastwave Medical, Lemaitre Vascular, Medtronic, Merit Medical, MicroPort Scientific, NirvaMed, Philips, Teleflex, Terumo, Translumina.

Global Markets for Oncology Embolization, 2023-2028
Published:
2023
Next Update:
Q4 2024
Deliverables:
excel pdf

This market snapshot from Life Science Intelligence provides an analysis of the global market for oncology embolization agents, including radioembolization, chemoembolization, and particle embolization devices. These solutions are used to occlude blood vessels to lesions and tumors to derive the target of nutrients, enhance the effectiveness of the targeted delivery of pharmaceuticals, and trigger cell death. This market snapshot is intended to provide a high-level overview of the global oncology embolization agents market, with key insights into: unit volumes from 2023 to 2028, market forecasts from 2023 to 2028, competitive landscape analysis of major competitors, and insights into key market events for strategics and startups. Companies covered in this report include: ABK Biomedical, Arsenal Medical, Boston Scientific, Cook, Cordis/Cardinal Health, Instylla, Medtronic, Merit Medical, Ned Medical, Obsidio, SirTex Medical, Stryker, Terumo, Varian.

Global Markets for Vascular Access Devices, 2023-2028
Published:
2023
Next Update:
Q4 2024
Deliverables:
excel pdf

This market snapshot from Life Science Intelligence offers an analysis of the global market for vascular access devices, which are essential for continuous and long-term access to the bloodstream for administering intravenous drugs and fluids. The market encompasses various types of devices, including peripherally inserted central catheters (PICC), midline catheters, central venous catheters (CVC), and implantable ports. The snapshot aims to provide a comprehensive overview of the global market for vascular access devices, offering key insights into unit volumes and market forecasts from 2023 to 2028. Additionally, it includes a competitive landscape analysis of major competitors and insights into key market events for both established players and startups. Companies covered in this report include: Access Vascular, AngioDynamics, B. Braun, Baxter, Becton, Dickinson & Company (BD), Bluegrass Vascular, C.R. Bard, Cook Medical, ICU Medical, Medline, Smiths Medical, Teleflex, Terumo, Vygon, and Yushin Medical.

Global Markets for Rotator Cuff Repair Suture Anchors, 2023-2028
Published:
2023
Next Update:
Q4 2024
Deliverables:
excel pdf

This market snapshot from LSI provides an analysis of the global market for rotator cuff repair suture anchors for the treatment of rotator cuff injuries. The market for rotator cuff repair suture anchors includes anchors composed of biocompatible polymers and metals. This market snapshot is intended to provide a high-level overview of the global market for rotator cuff repair suture anchors, with key insights into: unit volumes from 2023 to 2028, market forecasts from 2023 to 2028, competitive landscape analysis of major competitors, and insights into key market events for strategics and startups. Companies covered in this report include: Aevumed, Arthrex, Atreon Orthopedics, ConMed, DePuy Synthes, Embody, Inovedis, Smith & Nephew, Stryker, Tetrous, Wright Medical, Zimmer Biomet.

Global Markets for Electrical Stimulation Devices, 2023-2028
Published:
2023
Next Update:
Q4 2024
Deliverables:
excel pdf

Description coming soon.

Global Markets for Wearable Monitoring Devices, 2023-2028
Published:
2023
Next Update:
Q4 2024
Deliverables:
excel pdf

Description coming soon.

Global Markets for Low Complexity Medical Devices, 2023-2028
Published:
2023
Next Update:
Q4 2024
Deliverables:
excel pdf

Description coming soon.

Canada Surgical Procedure Volumes, 2018-2029
Published:
2022
Next Update:
Q2 2024
Deliverables:
excel report

The Canada Surgical Procedure Volumes Dashboard provides historical and forecasted volumes from 2018 to 2029 for Canada. Understand trends in procedure volume adoption and growth for over 200 procedures across 12 major procedure markets (Cardio, Ortho, General Surgery, OB/GYN, Urology and more). Data is updated and expanded annually to maintain a consistent pulse on the procedure utilization to empower strategic decisions on commercialization and new product development.

Germany Surgical Procedure Volumes, 2018-2029
Published:
2022
Next Update:
Q2 2024
Deliverables:
excel report

The Germany Surgical Procedure Volumes Dashboard provides historical and forecasted volumes from 2018 to 2029 for Germany. Understand trends in procedure volume adoption and growth for over 200 procedures across 12 major procedure markets (Cardio, Ortho, General Surgery, OB/GYN, Urology and more). Data is updated and expanded annually to maintain a consistent pulse on the procedure utilization to empower strategic decisions on commercialization and new product development.

France Surgical Procedure Volumes, 2018-2029
Published:
2022
Next Update:
Q2 2024
Deliverables:
excel report

The France Surgical Procedure Volumes Dashboard provides historical and forecasted volumes from 2018 to 2029 for France. Understand trends in procedure volume adoption and growth for over 200 procedures across 12 major procedure markets (Cardio, Ortho, General Surgery, OB/GYN, Urology and more). Data is updated and expanded annually to maintain a consistent pulse on the procedure utilization to empower strategic decisions on commercialization and new product development.

U.K. Surgical Procedure Volumes, 2018-2029
Published:
2022
Next Update:
Q2 2024
Deliverables:
excel report

The United Kingdom Surgical Procedure Volumes Dashboard provides historical and forecasted volumes from 2018 to 2029 for the United Kingdom. Understand trends in procedure volume adoption and growth for over 200 procedures across 12 major procedure markets (Cardio, Ortho, General Surgery, OB/GYN, Urology and more). Data is updated and expanded annually to maintain a consistent pulse on the procedure utilization to empower strategic decisions on commercialization and new product development.

Italy Surgical Procedure Volumes, 2018-2029
Published:
2022
Next Update:
Q2 2024
Deliverables:
excel report

The Italy Surgical Procedure Volumes Dashboard provides historical and forecasted volumes from 2018 to 2029 for Italy. Understand trends in procedure volume adoption and growth for over 200 procedures across 12 major procedure markets (Cardio, Ortho, General Surgery, OB/GYN, Urology and more). Data is updated and expanded annually to maintain a consistent pulse on the procedure utilization to empower strategic decisions on commercialization and new product development.

Spain Surgical Procedure Volumes, 2018-2029
Published:
2022
Next Update:
Q2 2024
Deliverables:
excel report

The Spain Surgical Procedure Volumes Dashboard provides historical and forecasted volumes from 2018 to 2029 for Spain. Understand trends in procedure volume adoption and growth for over 200 procedures across 12 major procedure markets (Cardio, Ortho, General Surgery, OB/GYN, Urology and more). Data is updated and expanded annually to maintain a consistent pulse on the procedure utilization to empower strategic decisions on commercialization and new product development.

Poland Surgical Procedure Volumes, 2018-2029
Published:
2022
Next Update:
Q2 2024
Deliverables:
excel report

The Poland Surgical Procedure Volumes Dashboard provides historical and forecasted volumes from 2018 to 2029 for Poland. Understand trends in procedure volume adoption and growth for over 200 procedures across 12 major procedure markets (Cardio, Ortho, General Surgery, OB/GYN, Urology and more). Data is updated and expanded annually to maintain a consistent pulse on the procedure utilization to empower strategic decisions on commercialization and new product development.

Netherlands Surgical Procedure Volumes, 2018-2029
Published:
2022
Next Update:
Q2 2024
Deliverables:
excel report

The Netherlands Surgical Procedure Volumes Dashboard provides historical and forecasted volumes from 2018 to 2029 for the Netherlands. Understand trends in procedure volume adoption and growth for over 200 procedures across 12 major procedure markets (Cardio, Ortho, General Surgery, OB/GYN, Urology and more). Data is updated and expanded annually to maintain a consistent pulse on the procedure utilization to empower strategic decisions on commercialization and new product development.

Belgium Surgical Procedure Volumes, 2018-2029
Published:
2022
Next Update:
Q2 2024
Deliverables:
excel report

The Belgium Surgical Procedure Volumes Dashboard provides historical and forecasted volumes from 2018 to 2029 for Belgium. Understand trends in procedure volume adoption and growth for over 200 procedures across 12 major procedure markets (Cardio, Ortho, General Surgery, OB/GYN, Urology and more). Data is updated and expanded annually to maintain a consistent pulse on the procedure utilization to empower strategic decisions on commercialization and new product development.

Sweden Surgical Procedure Volumes, 2018-2029
Published:
2022
Next Update:
Q2 2024
Deliverables:
excel report

The Sweden Surgical Procedure Volumes Dashboard provides historical and forecasted volumes from 2018 to 2029 for Sweden. Understand trends in procedure volume adoption and growth for over 200 procedures across 12 major procedure markets (Cardio, Ortho, General Surgery, OB/GYN, Urology and more). Data is updated and expanded annually to maintain a consistent pulse on the procedure utilization to empower strategic decisions on commercialization and new product development.

Switzerland Surgical Procedure Volumes, 2018-2029
Published:
2022
Next Update:
Q2 2024
Deliverables:
excel report

The Switzerland Surgical Procedure Volumes Dashboard provides historical and forecasted volumes from 2018 to 2029 for Switzerland. Understand trends in procedure volume adoption and growth for over 200 procedures across 12 major procedure markets (Cardio, Ortho, General Surgery, OB/GYN, Urology and more). Data is updated and expanded annually to maintain a consistent pulse on the procedure utilization to empower strategic decisions on commercialization and new product development.

Denmark Surgical Procedure Volumes, 2018-2029
Published:
2022
Next Update:
Q2 2024
Deliverables:
excel report

The Denmark Surgical Procedure Volumes Dashboard provides historical and forecasted volumes from 2018 to 2029 for Denmark. Understand trends in procedure volume adoption and growth for over 200 procedures across 12 major procedure markets (Cardio, Ortho, General Surgery, OB/GYN, Urology and more). Data is updated and expanded annually to maintain a consistent pulse on the procedure utilization to empower strategic decisions on commercialization and new product development.

Finland Surgical Procedure Volumes, 2018-2029
Published:
2022
Next Update:
Q2 2024
Deliverables:
excel report

The Finland Surgical Procedure Volumes Dashboard provides historical and forecasted volumes from 2018 to 2029 for Finland. Understand trends in procedure volume adoption and growth for over 200 procedures across 12 major procedure markets (Cardio, Ortho, General Surgery, OB/GYN, Urology and more). Data is updated and expanded annually to maintain a consistent pulse on the procedure utilization to empower strategic decisions on commercialization and new product development.

Norway Surgical Procedure Volumes, 2018-2029
Published:
2022
Next Update:
Q2 2024
Deliverables:
excel report

The Norway Surgical Procedure Volumes Dashboard provides historical and forecasted volumes from 2018 to 2029 for Norway. Understand trends in procedure volume adoption and growth for over 200 procedures across 12 major procedure markets (Cardio, Ortho, General Surgery, OB/GYN, Urology and more). Data is updated and expanded annually to maintain a consistent pulse on the procedure utilization to empower strategic decisions on commercialization and new product development.

China Surgical Procedure Volumes, 2018-2029
Published:
2022
Next Update:
Q2 2024
Deliverables:
excel report

The China Surgical Procedure Volumes Dashboard provides historical and forecasted volumes from 2018 to 2029 for China. Understand trends in procedure volume adoption and growth for over 200 procedures across 12 major procedure markets (Cardio, Ortho, General Surgery, OB/GYN, Urology and more). Data is updated and expanded annually to maintain a consistent pulse on the procedure utilization to empower strategic decisions on commercialization and new product development.

India Surgical Procedure Volumes, 2018-2029
Published:
2022
Next Update:
Q2 2024
Deliverables:
excel report

The India Surgical Procedure Volumes Dashboard provides historical and forecasted volumes from 2018 to 2029 for India. Understand trends in procedure volume adoption and growth for over 200 procedures across 12 major procedure markets (Cardio, Ortho, General Surgery, OB/GYN, Urology and more). Data is updated and expanded annually to maintain a consistent pulse on the procedure utilization to empower strategic decisions on commercialization and new product development.

Japan Surgical Procedure Volumes, 2018-2029
Published:
2022
Next Update:
Q2 2024
Deliverables:
excel report

The Japan Surgical Procedure Volumes Dashboard provides historical and forecasted volumes from 2018 to 2029 for Japan. Understand trends in procedure volume adoption and growth for over 200 procedures across 12 major procedure markets (Cardio, Ortho, General Surgery, OB/GYN, Urology and more). Data is updated and expanded annually to maintain a consistent pulse on the procedure utilization to empower strategic decisions on commercialization and new product development.

South Korea Surgical Procedure Volumes, 2018-2029
Published:
2022
Next Update:
Q2 2024
Deliverables:
excel report

The South Korea Surgical Procedure Volumes Dashboard provides historical and forecasted volumes from 2018 to 2029 for South Korea. Understand trends in procedure volume adoption and growth for over 200 procedures across 12 major procedure markets (Cardio, Ortho, General Surgery, OB/GYN, Urology and more). Data is updated and expanded annually to maintain a consistent pulse on the procedure utilization to empower strategic decisions on commercialization and new product development.

Australia Surgical Procedure Volumes, 2018-2029
Published:
2022
Next Update:
Q2 2024
Deliverables:
excel report

The Australia Surgical Procedure Volumes Dashboard provides historical and forecasted volumes from 2018 to 2029 for Australia. Understand trends in procedure volume adoption and growth for over 200 procedures across 12 major procedure markets (Cardio, Ortho, General Surgery, OB/GYN, Urology and more). Data is updated and expanded annually to maintain a consistent pulse on the procedure utilization to empower strategic decisions on commercialization and new product development.

Thailand Surgical Procedure Volumes, 2018-2029
Published:
2022
Next Update:
Q2 2024
Deliverables:
excel report

The Thailand Surgical Procedure Volumes Dashboard provides historical and forecasted volumes from 2018 to 2029 for Thailand. Understand trends in procedure volume adoption and growth for over 200 procedures across 12 major procedure markets (Cardio, Ortho, General Surgery, OB/GYN, Urology and more). Data is updated and expanded annually to maintain a consistent pulse on the procedure utilization to empower strategic decisions on commercialization and new product development.

Malaysia Surgical Procedure Volumes, 2018-2029
Published:
2022
Next Update:
Q2 2024
Deliverables:
excel report

The Malaysia Surgical Procedure Volumes Dashboard provides historical and forecasted volumes from 2018 to 2029 for Malaysia. Understand trends in procedure volume adoption and growth for over 200 procedures across 12 major procedure markets (Cardio, Ortho, General Surgery, OB/GYN, Urology and more). Data is updated and expanded annually to maintain a consistent pulse on the procedure utilization to empower strategic decisions on commercialization and new product development.

Singapore Surgical Procedure Volumes, 2018-2029
Published:
2022
Next Update:
Q2 2024
Deliverables:
excel report

The Singapore Surgical Procedure Volumes Dashboard provides historical and forecasted volumes from 2018 to 2029 for Singapore. Understand trends in procedure volume adoption and growth for over 200 procedures across 12 major procedure markets (Cardio, Ortho, General Surgery, OB/GYN, Urology and more). Data is updated and expanded annually to maintain a consistent pulse on the procedure utilization to empower strategic decisions on commercialization and new product development.

New Zealand Surgical Procedure Volumes, 2018-2029
Published:
2022
Next Update:
Q2 2024
Deliverables:
excel report

The New Zealand Surgical Procedure Volumes Dashboard provides historical and forecasted volumes from 2018 to 2029 for New Zealand. Understand trends in procedure volume adoption and growth for over 200 procedures across 12 major procedure markets (Cardio, Ortho, General Surgery, OB/GYN, Urology and more). Data is updated and expanded annually to maintain a consistent pulse on the procedure utilization to empower strategic decisions on commercialization and new product development.

Caribbean Surgical Procedure Volumes, 2018-2029
Published:
2022
Next Update:
Q2 2024
Deliverables:
excel report

The Caribbean Surgical Procedure Volumes Dashboard provides historical and forecasted volumes from 2018 to 2029 for the Caribbean region. Understand trends in procedure volume adoption and growth for over 200 procedures across 12 major procedure markets (Cardio, Ortho, General Surgery, OB/GYN, Urology and more). Data is updated and expanded annually to maintain a consistent pulse on the procedure utilization to empower strategic decisions on commercialization and new product development.

Argentina Surgical Procedure Volumes, 2018-2029
Published:
2022
Next Update:
Q2 2024
Deliverables:
excel report

The Argentina Surgical Procedure Volumes Dashboard provides historical and forecasted volumes from 2018 to 2029 for Argentina. Understand trends in procedure volume adoption and growth for over 200 procedures across 12 major procedure markets (Cardio, Ortho, General Surgery, OB/GYN, Urology and more). Data is updated and expanded annually to maintain a consistent pulse on the procedure utilization to empower strategic decisions on commercialization and new product development.

Colombia Surgical Procedure Volumes, 2018-2029
Published:
2022
Next Update:
Q2 2024
Deliverables:
excel report

The Colombia Surgical Procedure Volumes Dashboard provides historical and forecasted volumes from 2018 to 2029 for Colombia. Understand trends in procedure volume adoption and growth for over 200 procedures across 12 major procedure markets (Cardio, Ortho, General Surgery, OB/GYN, Urology and more). Data is updated and expanded annually to maintain a consistent pulse on the procedure utilization to empower strategic decisions on commercialization and new product development.

Chile Surgical Procedure Volumes, 2018-2029
Published:
2022
Next Update:
Q2 2024
Deliverables:
excel report

The Chile Surgical Procedure Volumes Dashboard provides historical and forecasted volumes from 2018 to 2029 for Chile. Understand trends in procedure volume adoption and growth for over 200 procedures across 12 major procedure markets (Cardio, Ortho, General Surgery, OB/GYN, Urology and more). Data is updated and expanded annually to maintain a consistent pulse on the procedure utilization to empower strategic decisions on commercialization and new product development.

Guatemala Surgical Procedure Volumes, 2018-2029
Published:
2022
Next Update:
Q2 2024
Deliverables:
excel report

The Guatemala Surgical Procedure Volumes Dashboard provides historical and forecasted volumes from 2018 to 2029 for Guatemala. Understand trends in procedure volume adoption and growth for over 200 procedures across 12 major procedure markets (Cardio, Ortho, General Surgery, OB/GYN, Urology and more). Data is updated and expanded annually to maintain a consistent pulse on the procedure utilization to empower strategic decisions on commercialization and new product development.

Dominican Republic Surgical Procedure Volumes, 2018-2029
Published:
2022
Next Update:
Q2 2024
Deliverables:
excel report

The Dominican Republic Surgical Procedure Volumes Dashboard provides historical and forecasted volumes from 2018 to 2029 for the Dominican Republic. Understand trends in procedure volume adoption and growth for over 200 procedures across 12 major procedure markets (Cardio, Ortho, General Surgery, OB/GYN, Urology and more). Data is updated and expanded annually to maintain a consistent pulse on the procedure utilization to empower strategic decisions on commercialization and new product development.

Costa Rica Surgical Procedure Volumes, 2018-2029
Published:
2022
Next Update:
Q2 2024
Deliverables:
excel report

The Costa Rica Surgical Procedure Volumes Dashboard provides historical and forecasted volumes from 2018 to 2029 for Costa Rica. Understand trends in procedure volume adoption and growth for over 200 procedures across 12 major procedure markets (Cardio, Ortho, General Surgery, OB/GYN, Urology and more). Data is updated and expanded annually to maintain a consistent pulse on the procedure utilization to empower strategic decisions on commercialization and new product development.

Panama Surgical Procedure Volumes, 2018-2029
Published:
2022
Next Update:
Q2 2024
Deliverables:
excel report

The Panama Surgical Procedure Volumes Dashboard provides historical and forecasted volumes from 2018 to 2029 for Panama. Understand trends in procedure volume adoption and growth for over 200 procedures across 12 major procedure markets (Cardio, Ortho, General Surgery, OB/GYN, Urology and more). Data is updated and expanded annually to maintain a consistent pulse on the procedure utilization to empower strategic decisions on commercialization and new product development.

Mexico Surgical Procedure Volumes, 2018-2029
Published:
2022
Next Update:
Q2 2024
Deliverables:
excel report

The Mexico Surgical Procedure Volumes Dashboard provides historical and forecasted volumes from 2018 to 2029 for Mexico. Understand trends in procedure volume adoption and growth for over 200 procedures across 12 major procedure markets (Cardio, Ortho, General Surgery, OB/GYN, Urology and more). Data is updated and expanded annually to maintain a consistent pulse on the procedure utilization to empower strategic decisions on commercialization and new product development.

Brazil Surgical Procedure Volumes, 2018-2029
Published:
2022
Next Update:
Q2 2024
Deliverables:
excel report

The Brazil Surgical Procedure Volumes Dashboard provides historical and forecasted volumes from 2018 to 2029 for Brazil. Understand trends in procedure volume adoption and growth for over 200 procedures across 12 major procedure markets (Cardio, Ortho, General Surgery, OB/GYN, Urology and more). Data is updated and expanded annually to maintain a consistent pulse on the procedure utilization to empower strategic decisions on commercialization and new product development.

Turkey Surgical Procedure Volumes, 2018-2029
Published:
2022
Next Update:
Q2 2024
Deliverables:
excel report

The Turkey Surgical Procedure Volumes Dashboard provides historical and forecasted volumes from 2018 to 2029 for Turkey. Understand trends in procedure volume adoption and growth for over 200 procedures across 12 major procedure markets (Cardio, Ortho, General Surgery, OB/GYN, Urology and more). Data is updated and expanded annually to maintain a consistent pulse on the procedure utilization to empower strategic decisions on commercialization and new product development.

Russia Surgical Procedure Volumes, 2018-2029
Published:
2022
Next Update:
Q2 2024
Deliverables:
excel report

The Russia Surgical Procedure Volumes Dashboard provides historical and forecasted volumes from 2018 to 2029 for Russia. Understand trends in procedure volume adoption and growth for over 200 procedures across 12 major procedure markets (Cardio, Ortho, General Surgery, OB/GYN, Urology and more). Data is updated and expanded annually to maintain a consistent pulse on the procedure utilization to empower strategic decisions on commercialization and new product development.

South Africa Surgical Procedure Volumes, 2018-2029
Published:
2022
Next Update:
Q2 2024
Deliverables:
excel report

The South Africa Surgical Procedure Volumes Dashboard provides historical and forecasted volumes from 2018 to 2029 for South Africa. Understand trends in procedure volume adoption and growth for over 200 procedures across 12 major procedure markets (Cardio, Ortho, General Surgery, OB/GYN, Urology and more). Data is updated and expanded annually to maintain a consistent pulse on the procedure utilization to empower strategic decisions on commercialization and new product development.
Schedule Meeting
Request Info
close
Video Transcription
close

Daniel Hawkins  0:05  
So I have to both take credit and apologize for the title. So founder is not necessarily CEO, right? That's just not as it's not a good bumper sticker, right? Founder not equal to CEO is a better bumper sticker. Yeah? Bumper sticker. This is really intended to take a cover off of the unspoken, which is the founder isn't necessarily, in the long term, the ultimate person to take the company forward. And note that it's not necessarily. It might be circumstances of company. Might be circumstances of individual. It might be circumstances that are related to performance of that individual capabilities. Might be a range of things. So what I'm going to ask everyone up on the panel with me here is to share in a short window, 2030, seconds worth background and how they come to have experiences on either side of the founder, CEO question, as the founder, who transitioned as the CEO, who took over as a board member, who forced the change, as a board member, who was accepting the desired change, as an investor involved in those decisions. Because I think it's important to understand the perspective from which everybody is gonna be giving some of their views. So if I could,


Paul LaViolette  1:26  
yeah, so I'm Paul LaViolette, 47 years in Medtech or thereabouts. And I did 15 years at Boston Scientific where for 10 of those years I worked for the founder Pete Nicholas, so large scale company, but nevertheless, founder transition, and then the last 1518, years, I've been a venture investor, been on 25 boards or so, and have certainly been through a few founder, CEO, professional management transitions. So I have it on both sides, but no one's ever accused me of being intelligent enough to found anything. So I'm not a founder myself, so I'll skip myself, and you guys can go ahead,


Kelly Constable  2:07  
sure. So Kelly Constable, I spent 20 years in industry on the pharma and biotech side, and then started building I was an intrapreneur. Started building digital assets inside of Amgen. I left eight years ago to become a full time entrepreneur. And the experiences that are relevant to this conversation is three times in the past eight years, I've been I've done turnarounds brought on by the investor taking the reins from founders, and then my current role is, I'm Chief Operating Officer of cloud Cath. This is not a turnaround, but I was brought on by the founder as CEO, and in about a month, he's handing the reins over to me, and I'll be taking on the role as CEO from the founder.


Todd Usen  2:49  
Hello, I'm Todd. You soon. I've been about 35 years in Medtech. I cut my teeth and spent about 14 of those at Boston Scientific last role I was my first opportunity to run a the country in the US, in a commercial for our neurovascular division, I moved over to Smith, and nephew in orthopedics, had a chance to various roles, and became the president of all of orthopedics. And then I, likewise, I did a presidency of all the medical businesses at Olympus. And then I went startup role and worked with a founder there and raised, raised a bunch of money and had some fun with that as a CEO. And then my last two I've taken over CEO roles of public companies from the founder. One shouldn't have been a public company, and, you know, we worked on that together. And the other one is we're in right now, so having a good time, and also sit on a few boards where we've had to make that transition as well.


Dan Sands  3:40  
Awesome. Dan sands, Managing Director of factor seven medical. The first 14 years of my career, I started at a startup and mentored by the two co founders for the first eight years, was a zero to 20 million very fun. Then I went to a larger company that was a merger of two companies to create symmetry medical. And within a year, I started a company for them that grew to 15 million in three years. Like this is a piece of cake. So I started my own solo and ran it for 10 years. And I went through this journey of founder, CEO, not CEO, back to CEO so and then I started the consulting group factor seven medical then, since I've taken several fractional CEO roles and dealt with a lot of different founder personalities over that 10 year, close to 30 different companies now interacting With founders and understanding what that their perspectives and and that of the investors to playing on both sides of the table can be pretty interesting at times. So looking forward to the discussion.


Daniel Hawkins  4:51  
So my background actually touches on all of these in many respects, I was a founder that was not supposed to be CEO, one of three founders of a company that. But we brought in a CEO that turned out miserably. Then I was founder of Shockwave medical, and made a determination, ultimately, that I wasn't the right person to go forward, ultimately, for personal reasons as well as I knew my limitations. So we brought in Doug, God chill, and he did a ridiculously good job. So that was a great experience. I've been on boards and watched it happen. I've been on boards and forced it happen. What I haven't done is the investor side, but what I hope you're seeing here is there's a range of reasons why these things could happen and perspectives to bring to bear. Somebody said to me earlier today, how did the word founder become a dirty word for clarity? It's not a dirty word. It's a word that's exceptional, and you should be honored to be one. But the reality is, the needs of the company might, over time, change, and as a result, your role might change. So what I put to the group here is, let's go from the perspective of many of us have taken over some circumstances around the takeover, and if you wouldn't mind, Paul, you were in an experience where one of the arguably more successful public companies had a founder, CEO, and then there was a transition. If you could share a little bit about as as somebody who was senior in that organization. What that was like? Yeah, well,


Paul LaViolette  6:25  
things change. The company grew. We grew 200,000,004 five 1,000,000,002 billion, 4 billion. Frankly, we started to fracture. We had problems. We weren't operating effectively. Todd was there. We would we would have recalls, we'd have manufacturing issue. And you look and say, you know, it's, these are infrastructure things. These are things that need to be attended to, that deep operating experience can address. But you know, if you're if you're a visionary, you don't really think that way. You're not paying attention to it. And so if you're a brilliant, visionary founder, you're so capable that you can do that for a while. You can do it for 100 200 400 million, at $5 billion it just doesn't work anymore. And so that I just think it's scale, it's the complexity of the business, it's the rate at which operating problems come. And at some point you say, you know, it's okay to grow really fast and to routinely have problems. That's the benefit of fast growth. But when the problems become so numerous that they're taking over for your ability to focus on growth, then you realize, you know what we need help.


Daniel Hawkins  7:43  
And Kelly, you were in some experiences where investors brought you in. Yes, talk about what it's like as the CEO coming in, and frankly, the dynamic with the founder, and then compare that to your current one. Oh, great


Kelly Constable  7:59  
question. Thanks. The first one was probably the most interesting. Interesting because I didn't expect to become CEO. I was brought in, and I joined a board, and I looked at the P and L, and probably was the first one. It was in Australia, and I said, either we do math differently in the southern hemisphere, or things aren't looking good. So I think it was within a day or two, I was asked to become the CEO, and that was a really interesting one, because it was a spin out from academic and was a genomic company. And for a while, the founder really enjoyed the turnaround that I was trying to lead, raising capital, deciding what was really a product, cutting restructuring. So he found it really exciting initially, but when we finally got down to signing the term sheet on the spin out, and I had found the capital, the first customer, et cetera, I said to him, you understand that now your behaviors need to change. We're taking on capital, so this time around, we need to behave in accordance with capital. It's not an academic grant. And he said, Well, what are those behaviors? And we started talking about accountability, all the things that you mentioned, infrastructure. And he looked me in the eye and said, I prefer keeping my autonomy. And so I would say to you that one was a really interesting dynamic, because at the end of the day, we shook hands and I closed the company down. I didn't continue to spin it out because I didn't have time with that tech team, and that tech team ultimately realized that what's required in your behaviors, whether you're the CEO or CTO or CMO with capital, is in conflict with what how they have their autonomy in an academic environment. So I wouldn't say it was controversial, but I would say it was very honest and transparent, and it was interesting to me, after they had run through 10s of millions of dollars, that they never understood what the behaviors look like in a private company that had capital until the very end. And so I would say it was sad. The difference with now is. That with Ali Al Badri, our founder, I would say, first of all, in regards to your comment about the dirty word, most of us would say, I have the utmost respect for founders. I would aspire to be that brilliant. It's a unique kind of intelligence. I have a lot of respect. I think that helps with our relationship. Ali is the respect for my founder, and also, I think Ali likewise respects that I bring a different skill set. So we're a team. We're work spouses, and I think it's going quite well. The driver of the change is we are both focused on return to shareholder, and that's probably, I would say, the winning recipe for why we work together so well,


Daniel Hawkins  10:41  
terrific. Todd, you had experiences coming into a public company where that is, to say the least, a storm when you're replacing the CEO. Share some brief thoughts on what it's like to do that in a very visible environment. Sure.


Todd Usen  11:01  
First, I don't know if you guys took it personally, but I did, when Paul said we had operating problems at Boston Scientific and then right away, said Todd was there. So I wasn't. I just I noticed that I'm sensitive. I took a free loves company, so I figured I was the cause. You know, it was very unique. And the first opportunity to do there was a great technology in women's health, and I had almost been groomed. And to be totally honest with you have leaders like Paul when you're growing up in a business like I was at Boston Scientific and then into Smith and Nephew, you have great mentors that you can rely on. So I was groomed at these large companies, at the level of a of a president, and with four and $5 billion P and Ls, and then I went startup. But then after you had success with that, you get the phone call, here's a technology we'd like you to consider coming back to the public world. Much smaller public company founder really had a great vision of the product. But was, was one of those. The founder was asked to maybe retire, you know, and not to, but, but was part of the recruiting process. The problem was the company shouldn't have been public. It was one of those that went public because they felt they had to, and so basically, we spent quite a bit of time in the public domain. You're basically everything you do, you're giving earnings reports, and you're, you know, you're constantly talking about the organization. You can't make big changes. You make an announcement on a press release that you're doing a restructuring, you know, which means you have to really remove some people. And doesn't matter how beautiful, well written it is, your stock's gonna go down. So, you know. And those things happen. And then at the end of the day, we were able to effectively, believe it or not, I now have a unique experience of selling it to private equity, because the stock was so low the amount of money that the private equity paid for it. When they own over 90% of a company, they can take it private, which was the right thing to do for the company. So it was a in a way, it was my first exit of selling something, and it turned out to be a public company, selling it to become private. So it was a little little battle reverse. We get it, hopefully, with class, with all the people along the way and made the company better and more much more profitable. Were there


Daniel Hawkins  13:14  
fireworks in the process,


Todd Usen  13:18  
I would say, and I can only say so much because I am a public company. Now, if you look in the sky where I am now, there'd be nice July 4 celebrations going on. So fair. And I might, you know, might be a little more, but that was, that was a different circumstance of technology, but fireworks, yes, in a sense that you need to know the people that are coming in. And there's private equity investors that are just remarkable. They're all remarkable, but they all have different visions. So as you know, the fireworks can be, you know now that they own it. Here's a decision, even if you're trying to help and work. But sometimes there's people jump into people decisions, and sometimes they jump into product decisions that they're basing it strictly on what they think is the return on investment versus what's best for the patient and the skill set of the company so that. But I don't think there. I think that's normal. I don't think first of all, there's no CEO job that doesn't have fireworks in it anyway, no matter how


Daniel Hawkins  14:18  
good. Well stated, yeah, well stated, you've had a lot of experience to cross a range. What nuggets would you share with the audience based on your experience? Boy,


Dan Sands  14:28  
so as a founder, I would say, you know, you're taking a lot of risk, and it's your baby, and you know, it's a true startup, and you've raised that capital, and you go through the rigor over the years, and you get to a point where, in a personal experience, the company hit certain milestones. And you know, based on, I guess, your self awareness and what your own capabilities, and what are the needs of the company, and just, you know, knowing you say, smart in. Have to know how dumb I am is really comes into play, and I think that leads to the humility of the founder and understanding the market and the expectations of investors, because when you take on investors, it's not your company anymore. And to have that understanding and to treat as such is very important, and so as investors, because I've evaluated and participated on the investment side, when you see founders really get, hey, this is mine, and that lack of understanding of what they're really trying to do is build value for others, is a very important trait. So I had the experience of one company that I found it I got to a certain point on that 10 year journey, is like I knew the company needed to do into a different vertical, the investors wanted it to go there. I didn't necessarily have the expertise, and I was the first one. I was like, I was ready for help. I wanted some others to come in, being capital constrained at the time, it's like you got to make some choices in what's best for the investor group. And so I went through that process with venture capital having a CEO come in that they wanted to bring in. And I was all for it. And then two years of execution, it became pretty apparent pretty quickly that it was not the right CEO, and it got really turbulent, both at the board level and with the employees too. They could sense things weren't going the way that you know, the plan outline. So, you know, it can, it can cut both ways. It's like, hey, the expectation of the founder, you have to perform hit milestones. If that's not there, you bring somebody in to do that. And there are situations where there's roadblocks, and I had to deal with the founder, brought somebody else in, and they weren't able to perform, and then it was like the board was looking at me. Is like, okay, Dan, now what? I'm like, Okay, we'll figure something out. And you just, you adapt and go. So I would say, if you're you're in that, that crosshair decision, whether led by the decision of the board or yourself, is to be open to the concept that there's no particular right way. If you're the founder, great at the end of the day, you're trying to create value from a financial perspective, and you just have to be open for those different scenarios and try to get to the finish line and win one piece.


Daniel Hawkins  17:44  
So totally agree. And lemme share a little bit of an experience that I think many in the audience might resonate particularly well with. You invented something, or you're a partner with somebody who invented something, and it's your baby. You're trying to take it forward, there's emotional investment in it. This is the three o'clock in the morning. You get up and you stare at the ceiling. Kind of investment. So when somebody else wants to take over, there's emotion involved in that. And I'm gonna caution avoidance of making that irrational emotion, right? So there's a sense of ownership that comes from the emotion. But at the end of the day, the reason you started the company, probably is the reason you shouldn't be running the company. Think about that for just a half minute, right? So there's great zero to one, zero to three, zero to four. Work that can happen, but zero to 10 work is rare in a single individual. So it took me some time at Chuck wave to realize one I had some personal reasons a young child I didn't spend much time with in the year prior to my decision to leave, but I also had the recognition that there was a 0% chance that I was going to take this to its ultimate potential. So I actually went and found somebody who I wanted to bring in as a Chief Operating Officer and as part of the recruiting I told him, I'm not going to mention his name, because he said no, so he's not going to want me to say who he is, but very experienced operator in the space. And I told him, I want you to do this job as CEO reporting to me for no more than 18 months, because I want you, I want you to then be my boss and take the company public. And that took a lot for me to go through, and I'm offering that not to say, hey, look, I was able to go through that story, but more to say, this is going to take a minute. There's a lot of emotion around that, but please remember why you started the company. You don't want to be the guy who's holding on, and the board is saying, that's a problem, and then you are exited. Okay? That's not a lot of fun for anyone. You also don't want to be the guy that is a guy or gal that's held on by the board when you shouldn't be there because now your company's not realizing what it should we've got a few minutes left. A lot of stories and perspectives have been shared. I thought it would be interesting if there's some thoughts from anyone in the audience that would want to share, ask a generalized question about how it's how it is to be on one side or another of all of this. If there aren't any that's fine. Lots more to to share. But wanted to offer that somebody up front


Audience Question  20:35  
here this, this is absolutely fascinating discussion. So I'm a strategic advisor to startups, and I've got two in particular that I'm thinking of, and I can see a train wreck happening into the future. So it it is incumbent on me and others, perhaps in the organization, to start to edge them towards the recognition of where things are going to go eventually. So I'm looking for a little of advice, what? How do you? How do you edge that founder, CEO that you know is going to be emotionally you described it very well. How do you, how do you coach them to avoid that, that that train work? Kelly, you gave an example where that didn't end well. So we don't want to go there. How do


Kelly Constable  21:20  
we? Great question, coach. I have a few examples, but let's use Ali and I as an example. And I mentioned this when we were having our pre conversation, and there were expectations. So when I interviewed for the role as CEO, I was transparent about my desires and spoke about it with the board as well as Ali, so so we all had a general understanding of the direction that this was going. I think one of the things, and also on the back of what Daniel said, I think as CEOs incoming, we also don't need to yank the baby either. You have a choice about how you go about that. So in regards to communicating, though, that message with Ali, we've talked more about it's not about he and I. We have a job to do, and that job is return to shareholders to drive value. If he wants to get his technology on a global platform, we have to do that. We all know that. So I think we've been quite objective and analytical instead of it being about Ali or Kelly, because it's not about me either. One of my interview questions was, how long do you want to be CEO? And I said, as long as I'm the right CEO, until I'm not the only answer, that's the only answer, right? So I think for Ali and I, we immediately took it not to be about us, but to be about the performance of the company. And once we understood what's the performance of the company to bring on more capital to get to the exit, well, then what is the, what is the roadmap to get there, and then what is the skill set required? And that requires bringing on more capital, more capital, expanding the team, increasing our product pipeline. Well, that skill set sits with me. Ali has got a different skill set. So I guess what I would say to you is, try to make it more objective, data driven, performance driven, and less about the individuals. And so because we are now focused on the same performance, we have the ability that I'll say to Ali, there are certain investors where I go, look. They're your style. You take them. Or there's other ones. We go, Kelly, this is yours, because we have a unified goal. So I would be fast, I would be transparent. I would not waste time, because if it's going to blow up with that founder, you've got an issue anyway, so you might as well get on with it, and hopefully they have the professionalism to focus on their job, which is return to shareholder.


Todd Usen  23:34  
So if I was going to add one thing there is, it's not just the CEO. So if you're looking at a company as a strategic advisor or not just a founder. I should say there's skill sets in every company that are ready to take a company from seed to A, A to B, and then to go, go to market, commercialize, etc. So the CEO just happens to be one of them that maybe we take this founder's brilliant ideas, whether they're engineer, doctor, whatever it is, we're going to build on that, and we're going to bring in, it's like baseball. We're going to bring in the closer, you know at the you know at the certain time, and you're just moving it on. But that's that's what I would communicate with a company in a smaller we're going to set you up for success, to deliver your vision, but we're going to make sure we have the right skill sets, and your skill sets are still needed in this role.


Daniel Hawkins  24:14  
Paul, you've had a lot of experience, I'm sure, with this as an investor. Does that look


Paul LaViolette  24:20  
like? Well, I think it's a great question, and I would look at it almost in a simple way. You break it down, what's a day in the life of the CEO? What are you doing today? What did you do a year ago, two years ago? And how are things going to change over the next year and the year after that? What are the demands of this role going to be? And let's look at the gaps that are emerging today, and they may be small. And you think, hey, we can probably work through those gaps, but let's be honest, the day in the life the job, whether it's dealing with investors or dealing with a larger employee base or more complex business, more operations. And you say, as we look this, look around the corner. Down the next three months, six months, 912, those gaps are only going to increase. And let's look at your skill set, which, by the way, your skill set as the founder, is remarkable. Again, we could not have done what you do and that, and that's not going to change, but the requirements of this role are changing, and the gaps are increasing, and if we honestly assess your skills, we say you're going to need to acquire this new skill. Okay, you're a talented person. You can acquire one skill, then you're going to need to acquire another one and another one. And now we're starting to kid ourselves that the most efficient way to manage this company is to continue to try to invest in your acquisition of new skills for a role for which you are not prepared. So honestly, and you mentioned this, Daniel, think it's great. Take the emotion out. It's but also be super sensitive to the fact we're dealing with people. You're fantastic. I've been CEO. I hate to tell you, CEO is not the most important job in the company at any given point in time, lots of other people are doing other fundamentally irreplaceable things, but we need the CEO to do what that individual needs to do. So let's find the right place for you to contribute. Let's find a role or a CEO to fill that job, and let's just admit that it's okay that you for all the value you've contributed, you don't need to be the CEO in order to contribute the most value to the company.


Daniel Hawkins  26:26  
That's 100% true. And I'm going to share a very brief experience of a founder situation where two of four board members, I was one of two, thought that that individual should, should become a not the CEO, but the founder and and it was clinically driven. So a clinical, you know, focused contributor and the chairperson had a different view, and that different view propagated and propagated and propagated to a point where the company was steering to the side and you could watch the wall approaching candidly as a board member, as an independent board member, I chose to actually just exit the situation, because it was not set up for anything like success, and the mission that I aligned with was now completely off course, and There was not any mindset towards doing what's right for the company at the board level. So it can actually go the other way, where the the founder is in the chair too long, because there might be some strength in a particular board, but I'm sure you've seen some of that where, you know, there's one or two quarters extra turned into four or five quarters extra turned into, we're on the cusp of the next financing. Gee, we can't change the founder before the financing turns into now it's after the financing the founder feels emboldened, and that mismatch has the makings of decreasing shareholder value at the end of the day, the emotional realization that you're great at some things and not great at all things is what's going to enable you to maximize shareholder value. If, as Kelly described, that's the ultimate goal that you have. So when I advise companies, one of the things I ask is, what's your goal? What are you trying to do? Did you start this company to be CEO? Then why aren't you a plumbing company? Why aren't you a landscaping company? What did you really start this company for? And at that point, there's a transitional realization. And I would ask those in the in the audience who are thinking about this for themselves and their own roles to think about that we don't have time for another question. We're going to take another one anyway.


Audience Question 2  28:46  
Well, full disclosure down, you've been very helpful for us and a wonderful advisor, Rob Israel, so I just have to say that. But I wanted to ask if the panel, if it can go the other way, and whether or not there's a CEO andor founder that can be supplemented in such a way that the board and the intelligence of the board, or maybe new folks on the board, can actually supplement that CEO or that founder to balance out some of the missing pieces along the way. And how does it work? The other way? Because, Daniel, you were just talking about how the boat tipped because of the CEO, can the board tip to the coachable CEO, or coachable founder, the other way, in your opinion. How might that supplement


Todd Usen  29:25  
it happens when it depends if you have a C, E, O, that has technical skills or medical skills. Oftentimes, in my situations, I've been brought in as a board member to offer the go to market or operations, but this found it's founder, CEO. He's fantastic, and I want to do everything I can to be his support and offer up that arm so but I know you didn't get a chance in the last one.


Dan Sands  29:49  
Well, I think it may depend on the makeup of the board and how well they're integrated, and then alignment. If there's alignment there, I. Think there's probably more openness for collaboration and making, you know, good modifications for the betterment. But I've, I've seen situations where there's not the right board alignment, and there's disparity, and then there's, you know, again, I think the the financial aspect of the founder, their ownership presented some of their rights from a voting perspective versus a board those, those are under currents, I think that really don't surface right out of the gate. And your example is like, what's the underlying expectation from the equity position? How much am I getting up? And do they really understand that that capital waterfall and erosion of that ownership percentage over time, and do they have a realistic expectation of what that really means over time? Because I've seen a really significant mismatch, and the board can't necessarily intermediate that if that is an underlying current of I've got to give up more ownership, and then I've got to give up authority and decision authority that I may not necessarily agree with that just, man, if you've got board, you know division of that board and people talking outside of the board meeting, just not a good situation,


Paul LaViolette  31:22  
but maybe one closing, I would be really careful about that. We're not replacing a CEO because they're not the right person to do the sales plan right. You can hire a sales person. You can hire another person to do almost anything. You can supplement with executive chairs and do all that. At some point you have to say, what is the leadership we're looking for? What leadership competencies does this person have? And if, if they're very close, and you can sort of fill the gap perhaps, with one thing, maybe, but be careful of the, you know, the patchwork quilt that you're creating. Like, well, we're going to patch over here. We're going to patch over here. Patch over like, as someone who likes to have a boat, like, at some point, stop patching the leaks. Get a new boat. So I just would encourage the board to be really mindful of that. That gap may may look like it's addressable today if we hire a chief this or chief that, or supplement with a board a director who's got this experience at some point, stop, you know, buttressing an individual who isn't right for the position, and just embrace the fact that the company will do better with a new person at the helm. And


Daniel Hawkins  32:37  
that's the exact situation I was referring to when I mentioned there's, there was a challenge where there wasn't board alignment, and, you know, three or four patches later, you've got a patchwork quilt, and that's not really what you want. We are out of time, which is disappointing, because I feel like there's a whole bunch of questions that are sitting there that haven't been asked. You know, to the extent any of us are available afterwards, certainly happy to chat now or up at the bar or what have you, but I'm getting the blinking red light. So thanks very much for your attention. 


Kelly Constable  33:10  
Thank You.